Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison
with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus
fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma.
To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in
paediatric patients with asthma.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance